Skip to main content
. Author manuscript; available in PMC: 2024 May 1.
Published in final edited form as: Arthritis Rheumatol. 2023 Mar 7;75(5):748–759. doi: 10.1002/art.42418

Fig. 3 – PR3-ANCA reactivity with iHm5 and iPR3 determined by anchor ELISA using serum from patients included in the WGET and in the RAVE trials.

Fig. 3 –

Scatter plot of the net absorbance values of iHm5 recognition plotted against iPR3 recognition using the anchor ELISA described with plasma and sera from patients of two AAV cohorts, the WGET (A) and the RAVE (B), respectively. There is a shift of the net absorbance values towards the binding of patient PR3-ANCA to iHm5. (Abbreviations: OD - optical density; PR3 - proteinase 3; RAVE – rituximab vs. cyclophosphamide for remission induction in AAV; WGET - Etanercept vs. placebo for remission induction in AAV)